Experimental Investigations into Sarcomas : Therapy Using Ferromagnetically Induced Cytostatics
https://libcat.nshealth.ca/en/permalink/provcat43149
Manfred Georg Krukemeyer.
--Wiesbaden:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
Manfred Georg Krukemeyer first describes magnetic drug targeting, by which is meant the focused application of drugs, e.g. the introduction of a cytostatic, and which is aimed at optimising its locally therapeutic effect. The author thus achieves a high concentration of cytostatic at the site of the tumour. The particles have to be large enough to be attracted by a magnetic field and so find their way into the tumour, where they release their active ingredient. The aim of the hypothesis formed …
- Available Online
- View e-Book
- Author
- Krukemeyer, Manfred Georg
- Responsibility
- Manfred Georg Krukemeyer
- Place of Publication
- Wiesbaden
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (xii, 122 p.) : 39 illus., 21 illus. in color
- ISBN
- 9783658205911
- 9783658205904 (print ed.)
- 9783658205928 (print ed.)
- Specialty
- Medical Oncology
- Abstract
- Manfred Georg Krukemeyer first describes magnetic drug targeting, by which is meant the focused application of drugs, e.g. the introduction of a cytostatic, and which is aimed at optimising its locally therapeutic effect. The author thus achieves a high concentration of cytostatic at the site of the tumour. The particles have to be large enough to be attracted by a magnetic field and so find their way into the tumour, where they release their active ingredient. The aim of the hypothesis formed by one of the author's study groups was to show in a scientific experiment that in this case cytostatics coupled with iron particles [Fe3O4] can be introduced into a tumour. The focused introduction of drugs—magnetic drug targeting—results in faster arrival of the active ingredient at the target site together with a reduced quantity of active substances. For this reason magnetic drug targeting is also interesting from an economic point of view. Contents: Sarcomas and their Pathology; Magnetic Drug Targeting; Animal Testing and Patient Examination; Tumour Therapy in Humans; Target groups; Researchers, teachers and students in surgical and oncology departments Doctors working in the fields of surgery and oncology. About the author: Dr. Manfred Georg Krukemeyer is a specialist surgeon currently holding a senior position at a large German hospital enterprise.
- Format
- e-Book
- Location
- Online
Prevention of Bone Metastases
https://libcat.nshealth.ca/en/permalink/provcat31127
Markus Joerger, Michael Gnant, editors.
--Berlin, Heidelberg:
Springer
, c2012.
- Available Online
- View e-Book
- Location
- Online
Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with br…
- Available Online
- View e-Book
- Other Authors
- Joerger, Markus
- Gnant, Michael
- Responsibility
- Markus Joerger, Michael Gnant, editors
- Place of Publication
- Berlin, Heidelberg
- Publisher
- Springer
- Date of Publication
- c2012
- Physical Description
- 1 online resource (ix, 233 p. : 23 ill., 13 ill. in color)
- Series Vol.
- 192
- Series Title
- Recent results in cancer research
- ISBN
- 9783642218927
- Subjects (MeSH)
- Biological Markers
- Bone Neoplasms - prevention & control
- Bone Neoplasms - secondary
- Cytostatic Agents - therapeutic use
- Diphosphonates - therapeutic use
- Subjects (LCSH)
- Oncology
- Abstract
- Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with breast, lung, and prostate cancer and disease progression in cases of multiple myeloma. The combined use of bisphosphonates and cytostatics is also discussed, with a report on first clinical data. Further topics addressed include the significance of the bone microenvironment, special issues in the elderly patient, the use of bone turnover markers, and initial findings obtained with denosumab.
- Contents
- Preclinical Models that Illuminate the Bone Metastasis Cascade -- The Role of Bone Microenvironment, Vitamin D and Calcium -- Bisphosphonates: Prevention of Bone Metastases in Breast Cancer -- Bisphosphonates: Prevention of Bone Metastases in Lung Cancer -- Bisphosphonates: Prevention of Bone Metastases in Prostate Cancer -- Targeting Bone in Myeloma -- Combinations of Bisphosphonates and Classical Anticancer Drugs: A Preclinical Perspective -- Perspectives in the Elderly Patient: Benefits and Limits of Bisphosphonates and Denosumab -- Denosumab: First Data and Ongoing Studies on the Prevention of Bone Metastases -- Diagnostic and Prognostic Use of Bone Turnover Markers -- Osteolytic and Osteoblastic Bone Metastases: Two Extremes of the Same Spectrum?
- Format
- e-Book
- Location
- Online
